Cargando…

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

BACKGROUND: The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge. Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signalling pathways in TNBC, resistance to EGFR-tyrosine kinase inhibitors (TKIs) rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLaughlin, Ronan P., He, Jichao, van der Noord, Vera E., Redel, Jevin, Foekens, John A., Martens, John W. M., Smid, Marcel, Zhang, Yinghui, van de Water, Bob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604188/ https://www.ncbi.nlm.nih.gov/pubmed/31262335 http://dx.doi.org/10.1186/s13058-019-1161-9

Ejemplares similares

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
por: van der Noord, Vera E., et al.
Publicado: (2019)

Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
por: He, Jichao, et al.
Publicado: (2019)

Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression
por: He, Jichao, et al.
Publicado: (2020)

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors
por: van der Noord, Vera E., et al.
Publicado: (2023)

Co-regulated gene expression of splicing factors as drivers of cancer progression
por: Koedoot, Esmee, et al.
Publicado: (2019)

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery
por: van der Noord, Vera E., et al.
Publicado: (2022)

Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors
por: Smith, Jennifer R., et al.
Publicado: (2008)

A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation
por: Chen, Elijah W., et al.
Publicado: (2019)

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models
por: Natoni, Alessandro, et al.
Publicado: (2013)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
por: Cremona, Mattia, et al.
Publicado: (2022)

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012)

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
por: Plangger, Adelina, et al.
Publicado: (2021)

Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors
por: Rupniewska, Ewa, et al.
Publicado: (2018)

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus
por: Hulin-Curtis, Sarah L., et al.
Publicado: (2018)

The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches
por: Li, Hong-Lian, et al.
Publicado: (2017)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
por: Meira, D D, et al.
Publicado: (2009)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy
por: Andreucci, Elena, et al.
Publicado: (2018)

Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML
por: O’ Reilly, Eimear, et al.
Publicado: (2018)

Development of CDK inhibitors as cancer therapeutics
por: Lane, D
Publicado: (2005)

CDK7 inhibitors as anticancer drugs
por: Sava, Georgina P., et al.
Publicado: (2020)

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
por: Majumdar, Abir, et al.
Publicado: (2021)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
por: Qin, Qiong, et al.
Publicado: (2020)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Low percentage of clinically relevant pistachio nut and mango co-sensitisation in cashew nut sensitised children
por: van der Valk, J. P. M., et al.
Publicado: (2017)

CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
por: Arsenijevic, Tatjana, et al.
Publicado: (2023)

Cdc48p is required for the cell cycle commitment point at Start via degradation of the G1-CDK inhibitor Far1p
por: Fu, Xinrong, et al.
Publicado: (2003)

Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin
por: Dilruba, Shahana, et al.
Publicado: (2020)

hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors
por: Gundogdu, Ramazan, et al.
Publicado: (2021)

Synthesis and Biological Evaluation of Indole-2-Carboxamides with Potent Apoptotic Antiproliferative Activity as EGFR/CDK2 Dual Inhibitors
por: Al-Wahaibi, Lamya H., et al.
Publicado: (2022)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers
por: Weerts, Marjolein J. A., et al.
Publicado: (2018)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Machine Learning Methods for Prediction of CDK-Inhibitors
por: Ramana, Jayashree, et al.
Publicado: (2010)

Highlights of the Latest Advances in Research on CDK Inhibitors
por: Cicenas, Jonas, et al.
Publicado: (2014)

Identification and Characterization of an Irreversible Inhibitor of CDK2
por: Anscombe, Elizabeth, et al.
Publicado: (2015)

CDK9 inhibitors in acute myeloid leukemia
por: Boffo, Silvia, et al.
Publicado: (2018)

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme
por: Lubanska, Dorota, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9a2qclkj449okmv73g0p2skmdu